CD274 and non-small cell lung carcinoma: On the same line, Martin-Delon et al. prospectively assessed stage III and IV NSCLC to evaluate the adequacy of EBUS-TBNA samples for molecular characterization, as assessed by NGS, nCounter and immunohistochemistry (PD-L1) and to compare its performance to the reference standard of biopsy samples.